Kenya

previous Print

HIV/AIDS Statistics for Kenya

Total population in thousands (2007): 37,538*
Number of people living with HIV (2007): 1,500,000 -- 2,000,000*
Adults aged 15 and up living with HIV (2007): 1,400,000-1,800,000*
Women aged 15 and up living with HIV (2007): 800,000-1,100,000*
Women aged 15 to 24 prevalence rate (2007): 4.6 -- 8.4*
Men aged 15 to 24 prevalence rate (2007): 0.8 -- 2.5*
Deaths due to AIDS (2007): 85,000 -- 130,000*
Estimated number of pregnant women living with HIV (2007): 76,000†


Ongoing biomedical HIV prevention research trials in Kenya
Vaccines Microbicides PrEP Partner Treatment

Vaccines

Trial: Evaluation of the safety and immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, boosted by a Multiclade HIV-1 Recombinant ADENOVIRUS-5 Vector Vaccine [RV 172]
Phase: I/II
Product Being Tested: A prime boost strategy with DNA vaccine with gag, pol, nef and env and adenovirus vector with gag, pol and env
Sponsor, funder, developer, collaborator: Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, Department of Health and Human Services, Vaccine Research Center, US Military HIV Research Program, US Army Medical Research Unit- Kenya/Kenya Medical Research Institute, Makerere University-Walter Reed Project, Mbeya Medical Research Program, Armed Forces Research Institute of Medical Services
Total participants: 324
Countries: Kenya, Tanzania, Uganda
Trial sites in Kenya: Kericho
Results expected: n/a
For more information: http://www.usamrukenya.org/rv172vaccinestudy.htm
Back to Top ↑

Microbicides

Trial: Safety and acceptability trial of dapivirine gel, conducted using daily monitored adherence in healthy HIV-negative women [IPM 014A]
Phase: I/II
Product Being Tested: Dapivirine gel
Sponsor, funder, developer, collaborator: International Partnership for Microbicides, Kenya Medical Research Institute
Total participants: 320
Countries: Kenya, Malawi, Rwanda, South Africa
Trial sites in Kenya: Kisumu
Results expected: July 2012
For more information: http://clinicaltrials.gov/ct2/show/NCT00917904?term=IPM014B&rank=1
Back to Top ↑

Pre-Exposure Prophylaxis

Trial: Study to assess the role of Truvada® in preventing HIV acquisition in women [FEM-PrEP]
Phase: III
Product Being Tested: Daily oral TDF/FTC (Truvada®)
Sponsor, funder, developer, collaborator: FHI; United States Agency for International Development; Bill and Melinda Gates Foundation; Bondo Clinic, Bondo District Hospital
Total participants: 3,900
Countries: Kenya, Malawi, South Africa, Tanzania, Zambia
Trial sites in Kenya: Nyanza
Results expected: 2013
For more information: http://clinicaltrials.gov/ct2/show/NCT00625404


Trial: Pre-Exposure Prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples [PartnersPrEP]
Phase: III
Product Being Tested: Daily oral TDF & daily oral TDF/FTC
Sponsor, funder, developer, collaborator: Bill and Melinda Gates Foundation; Moi University - Indiana University; Kenyatta National Hospital/University of Nairobi; CMR, Kemri-UCSF; Partners in Prevention - Thika
Total participants: 4,700
Countries: Kenya, Uganda
Trial sites in Kenya: Eldoret, Nairobi, Kisumu, Thika
Results expected: 2012
For more information: http://clinicaltrials.gov/ct2/show/NCT00557245


Trial: A pilot study of Pre-Exposure Prophylaxis (PrEP) to evaluate safety, acceptability, and adherence in at-risk populations in Kenya [IAVI E001]
Phase: I/II
Product Being Tested: Daily oral TDF/FTC; intermittent oral TDF/FTC (twice weekly + coital dosing)
Sponsor, funder, developer, collaborator: International AIDS Vaccine Initiative; Gilead Science, Inc; KEMRI-CGMRC, Kilifi, Kenya; KAVI-Kangemi, Kenya
Total participants: 72
Countries: Kenya, Uganda
Trial sites in Kenya: Kilifi, Kangemi
Results expected: Q4 2010
For more information: https://www.iavi.org/research-development/trials/pages/prepstudy.aspx
Back to Top ↑

Partner Treatment

Trial: Evaluation of the effectiveness of two antiretroviral treatment strategies to prevent HIV transmission in HIV-serodiscordant couples [HPTN 052]
Phase: III
Product Being Tested: Highly active antiretroviral therapy for HIV prevention
Sponsor, funder, developer, collaborator:HIV Prevention Trials Network, Gaborone Prevention/Treatment Trials CRS
Total participants: 1,750 couples
Countries: Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, US, Zimbabwe
Trial sites in Kenya: Kisumu
Results expected: n/a
For more information: http://www.hptn.org/research_studies/hptn052.asp


Trial: Safety and acceptability trial of dapivirine gel, conducted using daily monitored adherence in healthy HIV-negative women [IPM014A/B]
Phase: I/II
Product Being Tested: Dapivirine gel
Sponsor, funder, developer, collaborator: International Partnership for Microbicides, Kenya Medical Research Institute
Total participants: 320
Countries: Kenya, Malawi, Rwanda, South Africa, Tanzania
Trial sites in Kenya: Kisumu
Results expected: July 2012
For more information: http://clinicaltrials.gov/ct2/show/NCT00917904?term=IPM014B&rank=1
Back to Top ↑

*WHO, UNAIDS, and UNICEF. Epidemiological Fact Sheet on HIV and AIDS: Core data on epidemiological and response Kenya 2008 Update. 2008. http://www.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_KE.pdf
† WHO, UNAIDS, and UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: Progress Report. 2008. http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf